Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
Senmiao Technology is a very high risk China ride-hailing auto-services microcap. The filings show a small post-disposal operating base, continuing losses, material weaknesses, Nasdaq compliance pressure and potentially heavy dilution mechanics.
AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
A filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
Zymeworks Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zhengye Biotechnology Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zurn Elkay Water Solutions Corporation has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zevia PBC has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zura Bio Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zumiez Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zoetis reported FY2025 revenue of $9.47 billion and Q1 2026 revenue of $2.26 billion, with the official record tying the thesis to companion-animal demand, livestock cycles, product innovation, inventory quality, debt and cash conversion.
ZTO Express reported 2025 revenue of CNY 49.10 billion, operating income of CNY 10.47 billion and operating cash flow of CNY 11.97 billion. The thesis turns on China parcel volume, pricing, network efficiency, cash conversion and ADR governance risk.
YY Group Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zenta Group Company Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
AiRWA Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zentek Ltd. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
YXT.COM GROUP HOLDING LIMITED has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
ZeroStack Corp. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.